Drug – bio-affecting and body treating compositions – Sustained or differential release type
Patent
1997-09-22
1998-12-08
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Sustained or differential release type
424400, 514258, 514392, 514424, 514946, 514953, A61K 3140
Patent
active
058470107
ABSTRACT:
The present invention is a method of preventing or ameliorating the episodic recurrence of MS, comprising administering an effective amount of selective phosphodiesterase inhibitors of Type IV, e.g., Rolipram, e.g., wherein the severity of the episodic recurrences is ameliorated or the time period between episodes is lengthened.
REFERENCES:
patent: 4153713 (1979-05-01), Huth et al.
patent: 5227369 (1993-07-01), Rosen et al.
patent: 5420154 (1995-05-01), Chistensen et al.
patent: 5541219 (1996-07-01), Fenton et al.
C.D. Nicholson et al., "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", TiPS, vol. 12, Jan. 1991.
G. Dent et al., "Inhibition of Eosinophil Oxygen Radical Production by Type IV--But Not Type III--Selective cAMP Phosphodiesterase Inhibitors", Br. J. Pharm., vol. 22 (163P), 1990.
Wyngaarden et al., eds., "The Demyelinating Diseases", Cecil Textbook of Medicine, 19th Ed., pp. 2199-2200, 1992.
S. Nataf et al., "Pentoxifylline inhibits experimental allergic encephalomyelitis", Acta Neurol. Scand., vol. 88, pp. 97-99, 1993.
S.M. Taffet et al., "Regulation of Tumor Necrosis Factor Expression in a Macrophage-like Cell Line by Lipopolysaccharide and cyclic AMP", Cellular Immunology, vol. 120, pp. 291-300, 1989.
M.L. Reeves et al., "The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle", Biochem. J., vo. 241, pp. 535-541, 1987.
O. Rott et al., "Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats", Eur. J. Immunol., vol. 23, pp. 1745-1751, 1993.
F.U. Schade and c. Schudt, "The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophates", vol. 230, pp. 9-14, 1993.
"Multiple Sclerosis and Allied Demyellinative Diseases", Principles of Neurology, pp. 777-791, 1993.
Molnar-Kimber et al., "Differential regulation of TNF-.alpha. and IL-1.beta. production from endotoxin stimulated human monocytes by phosphodiesterase inhbitors", Mediators of Inflammation (1992).
Sharief et al., "Association Between Tumor Necrosis Factor-alpha . . . ", New England J. of Med., vol. 325, No. 7, pp. 467-472, Aug. 1991.
Benvenuto et al., "Increased Synthesis of Tumor Necrosis Factor . . . ", J. Neurol., vol. 237(SUP1), p. 83, 1990.
Kirby et al., "Prostacyclin Increases Cyclic-Nucleotide . . . ", The Lancet, vol. 2, No. 8192, pp. 453-454, Aug. 1980.
Renz et al., "Release of Tumor Necrosis Factor-.alpha. From Macrophages . . . ", J. of Immunology, pp. 2388-2393, Oct. 1988.
Strieter et al., "Cellular and Molecular Regulation of Tumor . . . ", Biochem. and Biophys. Research Comm., vol. 155, No. 3, pp. 1230-1236, Sep. 1988.
Spengler et al., "Dynamics of Cyclic AMP- and Prostaglandin . . . ", Infection and Immunity, vol. 57, No. 9, pp. 2837-2841, Sep. 1989.
Lloyd J. Old, "Tumor necrosis factor: Another chapter in the long . . . ", Nature, vol. 330, pp. 602-603, Dec. 1987.
Millar et al., "Tumour Necrosis Facter in Bronchopulmonary . . . ", Lancet, vol. II for 1989, pp. 712-714, Sep. 1989.
Tracey et al., "anti-cachectin/TNF monoclonal antibodies prevent . . . ", Nature, vol. 330, pp. 662-664, Dec. 1987.
Dezube et al., "Pentoxifylline and wellbeing in patients with cancer", Lancet, vol. 335, No. 8690, p. 662, Mar. 1990.
Frolich et al., "Is the Elevation of Cyclic . . . ", J. Invest. Dermat., vol. 90, No. 2, p. 240, 1988.
Marivet et al., "Inhibition of cyclic Adenosine-3',5'-monophospshate . . . ", J. Med. Chem., vol. 32, pp. 1450-1457, 1989.
Hedgpeth Joel
Wachtel Helmut
Berlex Laboratories Inc.
Raymond Richard L.
LandOfFree
Treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177790